Robert Rifkin, MD from Rocky Mountain Cancer Center discusses poster #1 phase 2 study of Daratumumab+ CyBorD and the dose was split into two days to reduce infusion time at the 2017 American Society of Hematology.
Poster #1 Phase 2 Study of Daratumumab+ CyBorD – Dose was split into two days to reduce infusion time
